December 13, 2017

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma

By

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma (CTCL).

Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s genome. Once a genetic abnormality is identified, a specific targeted therapy can be designed to attack a specific mutation or other cancer-related change in the DNA programming of the cancer cells. Precision cancer medicine uses targeted drugs and immunotherapies engineered to directly attack the cancer cells with specific abnormalities, leaving normal cells largely unharmed.  Because they are designed to specifically target cancer cells while leaving normal cells alone, targeted therapies usually have different, and sometimes milder, adverse side effects than standard chemotherapy drugs.

CTCL is a rare cancer of the white blood cells, specifically T lymphocytes, that primarily occurs in the skin. It is caused when T cells (cells in the immune system that help the body fight infection) begin to grow uncontrollably and build up in the skin. CTCL can also involve the blood, lymph nodes, and internal organs.

Mogamulizumab is a novel precision cancer medicine that is given intravenously and targets a protein (CCR4) that is frequently found on the surface of cancer cells in patients with CTCL. As a CCR4 antibody, the drug exploits the patient’s immune cells to attack the cancer.

In a head to head comparison the study found that the precision cancer medicine mogamulizumab improved progression-free survival, response rate, and quality of life compared to Zolinza™ (vorinostat), a U.S. Food and Drug Administration (FDA)-approved standard-of-care treatment for patients with CTCL.  Mogamulizumab

Reference

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study [817]

Copyright © 2018 CancerConnect. All Rights Reserved.

Tags: American Society of Hematology, ASH, Cutaneous T Cell Lymphoma, Mogamulizumab Vorinostat, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, Precision Cancer Medicine, T-Cell Non-Hodgkin's Lymphoma, targeted therapy, Uncategorized